These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38032933)
1. In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models. Goudy OJ; Nallathambi A; Kinjo T; Randolph NZ; Kuhlman B Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2307371120. PubMed ID: 38032933 [TBL] [Abstract][Full Text] [Related]
3. Design of a protease-activated PD-L1 inhibitor. Goudy OJ; Peng A; Tripathy A; Kuhlman B Protein Sci; 2023 Mar; 32(3):e4578. PubMed ID: 36705186 [TBL] [Abstract][Full Text] [Related]
4. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC. Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W Front Immunol; 2022; 13():828560. PubMed ID: 35464416 [TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering. Tseng TS; Lee CC; Chen PJ; Lin CY; Chen WC; Lee YC; Lin JH; Chen KW; Tsai KC J Chem Inf Model; 2024 Mar; 64(5):1615-1627. PubMed ID: 38356220 [TBL] [Abstract][Full Text] [Related]
6. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
7. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713 [No Abstract] [Full Text] [Related]
8. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy. Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579 [TBL] [Abstract][Full Text] [Related]
9. Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein. Gao ZZ; Li C; Chen G; Yuan JJ; Zhou YQ; Jiao JY; Nie L; Qi J; Yang Y; Chen SQ; Wang HB Protein Expr Purif; 2022 Jan; 189():105973. PubMed ID: 34560256 [TBL] [Abstract][Full Text] [Related]
11. Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression. Ligero M; Serna G; El Nahhas OSM; Sansano I; Mauchanski S; Viaplana C; Calderaro J; Toledo RA; Dienstmann R; Vanguri RS; Sauter JL; Sanchez-Vega F; Shah SP; Ramón Y Cajal S; Garralda E; Nuciforo P; Perez-Lopez R; Kather JN Cancer Res Commun; 2024 Jan; 4(1):92-102. PubMed ID: 38126740 [TBL] [Abstract][Full Text] [Related]
12. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Cembrola B; Ruzza V; Troise F; Esposito ML; Sasso E; Cafaro V; Passariello M; Visconte F; Raia M; Del Vecchio L; D'Alise AM; Cortese R; Scarselli E; Zambrano N; De Lorenzo C; Nicosia A Biomed Res Int; 2019; 2019():6051870. PubMed ID: 31976323 [TBL] [Abstract][Full Text] [Related]
13. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images. Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695 [TBL] [Abstract][Full Text] [Related]
14. Improving de novo protein binder design with deep learning. Bennett NR; Coventry B; Goreshnik I; Huang B; Allen A; Vafeados D; Peng YP; Dauparas J; Baek M; Stewart L; DiMaio F; De Munck S; Savvides SN; Baker D Nat Commun; 2023 May; 14(1):2625. PubMed ID: 37149653 [TBL] [Abstract][Full Text] [Related]
15. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). Kamalinia G; Engel BJ; Srinivasamani A; Grindel BJ; Ong JN; Curran MA; Takahashi TT; Millward SW; Roberts RW ACS Chem Biol; 2020 Jun; 15(6):1630-1641. PubMed ID: 32352272 [TBL] [Abstract][Full Text] [Related]
16. De novo design of protein interactions with learned surface fingerprints. Gainza P; Wehrle S; Van Hall-Beauvais A; Marchand A; Scheck A; Harteveld Z; Buckley S; Ni D; Tan S; Sverrisson F; Goverde C; Turelli P; Raclot C; Teslenko A; Pacesa M; Rosset S; Georgeon S; Marsden J; Petruzzella A; Liu K; Xu Z; Chai Y; Han P; Gao GF; Oricchio E; Fierz B; Trono D; Stahlberg H; Bronstein M; Correia BE Nature; 2023 May; 617(7959):176-184. PubMed ID: 37100904 [TBL] [Abstract][Full Text] [Related]
18. Development of a Non-IgG PD-1/PD-L1 Inhibitor by Ning B; Ren X; Hagiwara K; Takeoka S; Ito Y; Miyatake H ACS Chem Biol; 2021 Feb; 16(2):316-323. PubMed ID: 33448787 [TBL] [Abstract][Full Text] [Related]
19. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline. Mittal L; Tonk RK; Awasthi A; Asthana S Comput Biol Chem; 2023 Dec; 107():107965. PubMed ID: 37826990 [TBL] [Abstract][Full Text] [Related]
20. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Peng J; Zhang J; Zou D; Xiao L; Ma H; Zhang X; Li Y; Han L; Xie B Front Immunol; 2022; 13():960459. PubMed ID: 36420269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]